Chardan Capital reaffirmed their buy rating on shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) in a research report sent to investors on Tuesday. They currently have a $85.00 price target on the biopharmaceutical company’s stock.
Other equities research analysts have also issued research reports about the stock. BidaskClub lowered shares of La Jolla Pharmaceutical from a hold rating to a sell rating in a research note on Thursday, August 3rd. Jefferies Group LLC restated a buy rating and issued a $40.00 price target on shares of La Jolla Pharmaceutical in a research note on Tuesday, July 25th. Zacks Investment Research upgraded shares of La Jolla Pharmaceutical from a hold rating to a buy rating and set a $33.00 price target on the stock in a research note on Thursday, June 29th. Cowen and Company restated a buy rating and issued a $55.00 price target on shares of La Jolla Pharmaceutical in a research note on Friday, April 28th. Finally, ValuEngine upgraded shares of La Jolla Pharmaceutical from a sell rating to a hold rating in a research note on Friday, June 2nd. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $51.67.
La Jolla Pharmaceutical (NASDAQ:LJPC) traded up 1.39% during trading on Tuesday, reaching $30.57. The company’s stock had a trading volume of 141,077 shares. La Jolla Pharmaceutical has a 52 week low of $14.63 and a 52 week high of $39.28. The stock’s market capitalization is $676.30 million. The firm has a 50 day moving average of $31.59 and a 200 day moving average of $28.78.
La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.12) by $0.09. La Jolla Pharmaceutical had a negative net margin of 12,692.37% and a negative return on equity of 91.66%. During the same quarter last year, the business posted ($0.90) earnings per share. Analysts expect that La Jolla Pharmaceutical will post ($4.96) EPS for the current year.
TRADEMARK VIOLATION WARNING: “La Jolla Pharmaceutical Company (NASDAQ:LJPC) Rating Reiterated by Chardan Capital” was first published by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thestockobserver.com/2017/08/12/la-jolla-pharmaceutical-company-nasdaqljpc-rating-reiterated-by-chardan-capital.html.
Several hedge funds and other institutional investors have recently bought and sold shares of LJPC. State Street Corp raised its position in La Jolla Pharmaceutical by 6.3% in the fourth quarter. State Street Corp now owns 227,561 shares of the biopharmaceutical company’s stock worth $3,992,000 after buying an additional 13,495 shares in the last quarter. Teachers Advisors LLC raised its position in La Jolla Pharmaceutical by 12.4% in the fourth quarter. Teachers Advisors LLC now owns 25,390 shares of the biopharmaceutical company’s stock worth $445,000 after buying an additional 2,791 shares in the last quarter. Creative Planning bought a new position in La Jolla Pharmaceutical during the first quarter worth approximately $288,000. Essex Investment Management Co. LLC bought a new position in La Jolla Pharmaceutical during the first quarter worth approximately $483,000. Finally, Jennison Associates LLC raised its position in La Jolla Pharmaceutical by 586.1% in the first quarter. Jennison Associates LLC now owns 1,768,213 shares of the biopharmaceutical company’s stock worth $52,781,000 after buying an additional 1,510,504 shares in the last quarter.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with MarketBeat.com's FREE daily email newsletter.